The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.
Males and females 30 to 70 years of age
The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)
High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg/L
The presence of severe rosacea as noted by the investigator global assessment.
Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.
Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment
Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.